Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The immune response to AIDS virus infection: good, bad, or both?
Steven G. Deeks, Bruce D. Walker
Steven G. Deeks, Bruce D. Walker
Published March 15, 2004
Citation Information: J Clin Invest. 2004;113(6):808-810. https://doi.org/10.1172/JCI21318.
View: Text | PDF
Commentary

The immune response to AIDS virus infection: good, bad, or both?

  • Text
  • PDF
Abstract

A potent antigen-specific T cell response to HIV infection can contribute to the control of viral replication and is therefore beneficial to the host. However, HIV-mediated increases in generalized T cell activation also appear to accelerate both viral replication and CD4+ T cell depletion. A new study in the JCI attempts to experimentally distinguish the beneficial versus harmful aspects of this immune response.

Authors

Steven G. Deeks, Bruce D. Walker

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Schematic figure illustrating the impact of fitness and pathogenicity on...
Schematic figure illustrating the impact of fitness and pathogenicity on virus-host outcomes. (A) Highly fit, pathogenic virus: HIV-1 in most antiretroviral-untreated humans and SIV in rhesus macaques is both highly fit (i.e., replicates at high levels) and highly pathogenic (i.e., causes T cell depletion and disease). (B) Poorly fit virus: highly pathogenic viruses may cause limited disease if replication is limited. HIV-1 under successful antiretroviral treatment and HIV-1 being controlled immunologically are examples of environments whereby HIV-1 is unable to replicate efficiently and is therefore poorly fit. Most therapeutic strategies are aimed at reducing the capacity of HIV-1 to replicate efficiently. (C) Less pathogenic virus: SIV in sooty mangabeys replicates efficiently and is therefore highly fit. This virus, however, does not consistently cause disease, suggesting that its pathogenic effect has been attenuated. There has been only a limited amount of investigation aimed at reducing the pathogenic effect of HIV-1 in humans.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts